Skip to content

Evaluation of the effect of N-acetyl cysteine on the prognosis of hospitalized children with covid 19 : a pilot-randomized-double blinded-placebo-controlled clinical trial

Evaluation of the effect of N-acetyl cysteine on the prognosis of hospitalized children with covid 19 : a pilot-randomized-double blinded-placebo-controlled clinical trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
IRCT
Registry ID
IRCT20220516054879N1
Enrollment
40
Registered
2022-06-11
Start date
2022-05-31
Completion date
Unknown
Last updated
2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

covid 19. covid-19 , virus identified

Interventions

Intervention 1: Intervention group: in this trial we will use effervescent tablets of NAC from osveh company with dose of 600 mg BD , duration of prescription is 7 days or until discharge. Interventio

Sponsors

Rasht University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
8 Years to 18 Years

Inclusion criteria

Inclusion criteria: every child with 8 to 18 ages of year with clinical diagnosis of covid including positive PCR test and chest radiography coming to 17 sahrivar hospital in rasht.

Exclusion criteria

Exclusion criteria: parents or patients dissatisfaction for participating in study patients with severe covid or patients who hospitalized in ICU

Design outcomes

Primary

MeasureTime frame
Duration of need to ventilator. Timepoint: desired factor will measure at first of hospitalization then after 7 days or at the time of discharge. Method of measurement: the prognosis of patients with time of hospitalization and the period of time need to ventilator and status at the time of discharge will evaluate.;Improvement of clinical signs and oxygenation. Timepoint: desired factor will measure at first of hospitalization then after 7 days or at the time of discharge. Method of measurement: the prognosis of patients with time of hospitalization and the period of time need to ventilator and status at the time of discharge will evaluate.;CRP inflammatory factor. Timepoint: desired factor will measure at first of hospitalization then after 7 days or at the time of discharge. Method of measurement: the prognosis of patients with time of hospitalization and the period of time need to ventilator and status at the time of discharge will evaluate.;Hospitalization in the intensive care unit. Timepoint: will be checked if transfer occur. Method of measurement: the prognosis of patients with time of hospitalization and the period of time need to ventilator and status at the time of discharge will evaluate.;Patient status at discharge. Timepoint: at the discharge. Method of measurement: the prognosis of patients with time of hospitalization and the period of time need to ventilator and status at the time of discharge will evaluate.

Secondary

MeasureTime frame
Secondary variable is patient status at the time of discharge(recovery). Timepoint: at the discharge. Method of measurement: order and diagnosis of pediatrician.;Secondary variable is patient status at the time of discharge (transfer to the intensive care unit or death). Timepoint: at the discharge or transfer. Method of measurement: order and diagnosis of pediatrician.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMaryam Shahrokhi

Rasht University of Medical Sciences

17shahrivar@gums.ac.ir+98 13 3336 9019

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026